Genentech Recalls Prescription Drug Evrysdi Due to Failure to Meet Child Resistant Packaging Requirements; Risk of Drug Exposure through Eye or Skin Absorption (Recall Alert)

What was recalled

The U.S. Consumer Product Safety Commission (CPSC) announced a significant recall on March 18, 2021, involving specific bottles of the prescription medication Evrysdi. This drug, manufactured by Genentech, is a critical treatment for spinal muscular atrophy (SMA), a serious genetic condition that affects muscle strength and movement in both adults and children aged two months and older. While the medication itself remains effective and safe for its intended medical purpose, the specific containers holding it were found to have a manufacturing defect that compromised their safety standards.

The items subject to this recall are exclusively the 100 mL amber bottles of Evrysdi (risdiplam) for oral solution. These are not generic or third-party products; they are specifically branded under Genentech. To identify whether your bottle is part of this recall, you must look closely at the front label. The affected bottles will clearly display the text "Evrysdi (risdiplam) for oral solution" along with the specific dosage information. Most importantly, you need to check for the National Drug Code (NDC) number printed on the label. Only bottles bearing the NDC 20242-175-07 are included in this recall action.

The core of the issue lies not in the chemical composition of the drug, but in the physical construction of the bottle’s closure system. The defect involves a fit issue between the press-in bottle adapter and the bottleneck of the container. This mechanical mismatch can allow the liquid medication to leak out of the bottle. Because Evrysdi is a potent prescription drug, it is required by federal law to be packaged in child-resistant containers that prevent young children from accessing its contents. The leakage defect undermines this essential safety feature, creating a potential pathway for accidental exposure.

While the recall alert does not specify the exact retail locations or geographic regions where these bottles were originally sold, it confirms that Genentech has identified all known purchasers of these specific units. Upon discovering the issue, the company initiated direct contact with every customer who had purchased the affected product to inform them of the situation. This proactive approach ensures that individuals who may have received these bottles through various pharmacy channels are aware of the potential risk and know how to proceed.

To date, Genentech has received 26 reports of leaking bottles associated with this defect. It is reassuring to note that despite these leaks, no injuries have been reported to the company or the CPSC. However, the presence of any leak indicates that the bottle’s integrity has been compromised regarding its child-resistant design. If you possess a 100 mL amber bottle of Evrysdi with the NDC 20242-175-07, it is vital to treat it as part of this recall until you have verified its status and taken the appropriate steps outlined by Genentech.

The hazard, explained

To understand the risk here, we need to look at exactly how the packaging is supposed to work and where that mechanism failed in this specific instance. The prescription drug Evrysdi comes in amber bottles designed to protect both the medication’s stability and the user’s safety. A critical component of this protection is the press-in bottle adapter, a piece that seals the top of the bottle. In the recalled units, there is a fit issue between this adapter and the bottleneck of the container. Because the parts do not align or seal correctly, the bottle can leak. This isn't just a minor inconvenience; it means the contents are escaping the controlled environment of the vial.

When a bottle leaks, the liquid medication is no longer contained. This creates two distinct pathways for harm. First, the leaking fluid can come into direct contact with your skin or eyes. Evrysdi (risdiplam) is a potent prescription medicine used to treat spinal muscular atrophy. While it is effective when taken orally as directed, exposure through the skin or eyes poses a different kind of risk. The drug can be absorbed through these tissues, potentially leading to unintended systemic exposure. This is why immediate washing with soap and water for skin contact, or rinsing with water for eye contact, is the recommended first response.

The second, and perhaps more critical danger, involves child safety laws and physical access. By federal law, prescription drugs must be packaged in child-resistant containers to prevent children from gaining access to the contents. This requirement exists because accidental ingestion by children can lead to severe poisoning or death. The failure of the bottle’s seal compromises this barrier. If a child were to handle a leaking bottle, they might get the medication on their hands and then rub their eyes or mouth, or worse, ingest it directly if the cap is removed. The CPSC emphasizes that the primary concern is preventing any contact with children, as even small amounts of certain medications can be toxic to them.

It is important to note that while the leakage indicates a packaging failure, Genentech has stated that the leakage itself is not anticipated to impact the safety or efficacy of the medicine for the person using it as directed. However, the risk is not about the drug’s potency; it is about the uncontrolled release of the drug outside its intended delivery method. With 26 reports of leaking bottles already logged, the physical defect is real and present. The lack of reported injuries so far is reassuring, but it does not eliminate the potential for harm if the situation escalates or if a child encounters a leaky bottle. Understanding this mechanical failure helps explain why the remedy involves replacing the bottle entirely rather than just cleaning it—the seal itself is fundamentally compromised.

Who is most at risk

When we look at this specific recall concerning Genentech’s prescription drug Evrysdi, the primary group of concern is not just the individual taking the medication, but specifically the children living within their household. Evrysdi is a critical treatment for spinal muscular atrophy (SMA), a serious genetic disease that affects muscle strength and movement. Because this medication is prescribed to both adults and children as young as two months old, it is often present in homes where younger siblings or other toddlers are also present. The core of the risk here stems from a mechanical failure in the packaging itself. The bottles have a fit issue between the press-in bottle adapter and the bottleneck, which can cause the container to leak. This means that the medication is no longer safely contained within its protective vessel, potentially exposing anyone who handles the bottle or comes into contact with the leaked liquid.

The individuals most vulnerable to harm in this scenario are young children, particularly those under the age of five. Young children are naturally curious and explore their environment by touching everything they see. If a bottle is leaking, the medication may be present on the outside of the container or on surfaces nearby where it was placed. Children have thinner skin than adults, which allows substances to be absorbed into the body more readily. Furthermore, they frequently put their hands in their mouths or rub their eyes after touching objects, creating a direct pathway for drug exposure through both skin contact and accidental ingestion or eye absorption. The Poison Prevention Packaging Act exists specifically because children are so susceptible to accidental poisoning; they lack the cognitive understanding of danger and the physical dexterity to open secure containers, yet the failure of this specific packaging means the barrier is compromised before they even try.

While adults are also at risk, their vulnerability is slightly different. Adults generally have thicker skin and better hygiene habits, such as washing hands after handling medications. However, adults who administer the drug to young children face a secondary risk: if they do not notice the leak, they may inadvertently transfer the medication to the child’s skin or eyes during the feeding process. Additionally, any individual with sensitive skin or pre-existing eye conditions could experience irritation or adverse reactions from direct contact with the drug. It is important to note that while no injuries have been reported in the 26 known cases of leaking bottles, the potential for harm remains real because the nature of prescription drugs means they are potent and not intended for external use. The risk is highest for households with toddlers who can crawl or walk and explore countertops or tables where these amber bottles might be stored temporarily.

How to tell if you have the recalled item

Before you take any action or contact Genentech, it is essential to confirm that your specific bottle of Evrysdi is part of this recall. Because pharmaceutical recalls are often limited to particular batches or manufacturing runs, checking the physical details of your medication is the only way to be certain you are affected. This step might feel like a small logistical hurdle, but it is the most important part of staying safe, as it prevents unnecessary worry if your bottle is not included in this specific safety alert.

The primary identifier for the recalled products is the National Drug Code (NDC) number printed on the label. You need to locate the front of the bottle and look closely at the printed text. The recalled items are specifically the 100 mL amber bottles that display "Evrysdi (risdiplam) for oral solution" along with the dosage information. Crucially, the NDC code on these bottles will be exactly 20242-175-07. If your bottle has a different NDC number, it is not part of this recall. Please note that while the size (100 mL) and the amber color are characteristic of this product, the NDC code is the definitive proof of whether your specific unit is included in the Genentech safety alert.

If you cannot find the NDC number on the bottle itself, or if the label is worn or difficult to read, do not guess. Instead, check the packaging materials that came with your prescription. The outer carton or any accompanying documentation often lists the full NDC and batch details clearly. Genentech has stated that they are contacting all known purchasers directly, which means they have records of who received these specific bottles. However, relying on their outreach alone may cause delays in addressing potential leaks.

It is also helpful to understand why you are looking for this code. This recall involves a mechanical fit issue between the press-in bottle adapter and the bottleneck, which can cause leaking. Only bottles with the specific configuration identified by NDC 20242-175-07 are at risk of this defect. By verifying this number, you ensure that you are focusing your attention on the products that actually require inspection for leakage. If you have multiple bottles, check each one individually, as recalls often affect only a subset of distributed inventory.

If you are unsure about how to read the NDC or if you have lost the packaging, remember that Genentech is actively working to identify affected customers. However, taking the time to inspect the front label of your amber 100 mL bottle now provides immediate clarity and allows you to proceed with the correct next steps without delay.

What to do — step by step

Your refund, repair, or replacement options

If you have been prescribed Evrysdi and are concerned about the integrity of your current bottle, it is important to understand that Genentech has established a clear and accessible remedy for this specific recall. The primary action being offered is a free replacement of the affected product. This is not a situation where you need to navigate complex return logistics or pay for shipping; the company is taking full responsibility for ensuring you receive safe, compliant medication without additional cost to you. Because the issue stems from a manufacturing defect in the packaging rather than the drug itself, the focus is on getting you a bottle that meets all required safety standards, specifically those mandated by the Poison Prevention Packaging Act.

To initiate this process, you do not need to wait for a letter if you have already identified the problem. While Genentech has stated they are contacting all known purchasers directly to inform them of this recall, proactive contact is encouraged if you wish to secure your replacement immediately or if you have not yet received communication from them. You can reach Genentech’s dedicated support team by calling 800-334-0290. This line is available during standard business hours, specifically from 8 a.m. to 8 p.m. Eastern Time, Monday through Friday. Speaking with a representative will allow you to verify your specific lot details and arrange for the shipment of a replacement bottle. Alternatively, if you prefer to handle this online, you can visit www.Evrysdi.com. On the homepage, look for the prominent banner labeled "leaking bottles safety information." Clicking this link will guide you through the necessary steps to request your free replacement.

It is crucial to note that while you arrange for your replacement, you are not necessarily required to stop using the medication immediately if the bottle is not currently leaking. The recall notice indicates that the leakage issue is related to the fit between the press-in bottle adapter and the bottleneck. Consequently, the safety and efficacy of the medicine itself have not been compromised by this packaging flaw. You may continue to use the drug as directed by your healthcare provider while you wait for your replacement, provided you take extra care to store it in a safe location out of reach and sight of children.

If you do discover that your bottle is leaking, the remedy involves two immediate steps. First, contact Genentech using the methods described above to request your free replacement. Second, if any of the medication has come into contact with your skin or eyes due to the leak, rinse the affected area thoroughly with soap and water (for skin) or plain water (for eyes). There are no reported injuries associated with this recall, but prompt cleaning is a sensible precautionary measure. Remember, the goal here is simply to ensure you have packaging that properly protects your family from accidental exposure while maintaining your treatment plan for spinal muscular atrophy.

What can happen if you ignore it

It is completely understandable why you might hesitate to act immediately on a recall notification. When you are managing a serious medical condition like spinal muscular atrophy (SMA), the thought of interrupting your routine, dealing with customer service calls, or waiting for a replacement can feel overwhelming. You may look at the bottle and think, "It only looks like a tiny leak," or "I haven't had any problems yet." However, ignoring this specific recall carries real, tangible risks that extend far beyond just a messy countertop. The core issue here is not merely about waste; it is about the integrity of safety protocols designed to protect vulnerable individuals from unintended drug exposure.

The most immediate consequence of ignoring a leaking Evrysdi bottle is the risk of accidental dermal or ocular contact with the medication. Because the fit between the press-in bottle adapter and the bottleneck has failed, the liquid medicine is escaping its intended container. If you continue to use this bottle without replacing it, every time you handle it, there is a chance that the drug will come into contact with your skin or eyes. While Evrysdi is a powerful prescription medication designed for oral ingestion, absorbing it through the skin or eyes is not how it is meant to be taken. Your body processes drugs differently depending on the route of entry. Contact absorption can lead to unpredictable systemic levels of the drug in your bloodstream, potentially causing side effects that are different from, or more severe than, those experienced when taking the medication as directed. Even if you do not feel immediate irritation, repeated exposure without proper containment increases the likelihood of adverse reactions over time.

A far more critical consequence involves the safety of children and other household members who may not be aware of the danger. The recall was issued because the bottles failed to meet the strict child-resistant packaging requirements mandated by the Poison Prevention Packaging Act (PPPA). This act exists for a reason: standard caps cannot prevent determined toddlers from opening containers, but properly fitted child-resistant adapters can create a significant barrier. When that adapter fails and the bottle leaks, it compromises the entire safety architecture of the package. If a child were to come into contact with the leaked residue on your hands, clothing, or nearby surfaces, they could ingest or absorb a dose of medication intended for an adult or an older child. This is not a hypothetical scenario; Genentech has already documented 26 instances of leaking bottles. While no injuries have been reported so far, the absence of injury in past incidents does not guarantee safety in future ones. A single instance of accidental exposure by a small child could result in serious medical emergency, requiring immediate hospitalization.

Furthermore, ignoring the leak creates a false sense of security regarding the medication itself. While Genentech notes that the leakage is not anticipated to impact the safety or efficacy of the medicine *inside* the bottle for the patient using it, the external environment becomes contaminated. This means that your daily routine becomes a vector for potential exposure. You might unknowingly transfer traces of the drug to door handles, remote controls, or other family members’ skin. By continuing to use the recalled item, you are essentially ignoring a known failure in safety engineering. The remedy is straightforward—a free replacement—but the cost of ignoring it is an unnecessary and preventable risk to your household’s health. Taking action now ensures that your treatment continues safely without compromising the physical safety of everyone around you.

Staying safe: broader tips

While this specific recall addresses a manufacturing defect in prescription drug packaging, the underlying principle is one of universal importance for every household with children or individuals who may be vulnerable to accidental exposure: proactive prevention is always more effective than reactive management. When it comes to medications, especially those prescribed for serious conditions like spinal muscular atrophy, safety extends far beyond the moment of administration. It requires a holistic approach to how medicines are stored, monitored, and managed within your home environment.

First and foremost, establish a "secure zone" for all pharmaceuticals. This does not mean simply locking them in a medicine cabinet; it means storing them in a location that is both physically inaccessible to curious hands and visually out of sight. Children are driven by curiosity and mimicry. If they can see the bottle on a counter or in an open bin, the temptation to investigate increases exponentially. Use high-reach shelves or locked cabinets that require a key or combination, ensuring that the storage method itself is resistant to tampering by young children who may have learned to open standard latches. Regularly audit your medicine cabinet not just for expired drugs, but for any containers that appear damaged, discolored, or improperly sealed.

Education is another critical layer of defense. For older children and teenagers, have open, age-appropriate conversations about the difference between food, candy, and medication. Teach them that if they find an unlabeled bottle or a container that looks like it might be medicine, they should never taste it to "check" what it is. Instead, they should leave it alone and tell an adult immediately. For younger children, reinforce the concept of "grown-up only" items through consistent messaging and by keeping all non-essential items out of their immediate reach and awareness.

Beyond the home, stay informed about the broader landscape of product safety. Subscribe to alerts from the Consumer Product Safety Commission (CPSC) and the Food and Drug Administration (FDA). These agencies issue recalls not just for toys or appliances, but for everyday items like clothing, electronics, and, as seen in this case, pharmaceutical packaging. A quick weekly check of recall databases can help you identify potential hazards before they cause harm. Additionally, consider installing carbon monoxide detectors on every level of your home and testing smoke alarms monthly. These devices are silent guardians that provide an extra layer of protection against invisible threats, much like proper drug storage protects against accidental ingestion or absorption.

Finally, remember that safety is a shared responsibility. If you share care of a child with grandparents, babysitters, or other family members, ensure they are fully aware of your storage protocols and emergency procedures. Provide them with clear instructions on what to do in case of exposure, including the contact information for poison control (1-800-222-1222) and the specific manufacturer’s support line. By building these habits now, you create a resilient safety net that protects your family long after any single recall has been resolved.